Marjan Yaghmaie

Prof. Dr. Marjan Yaghmaie


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2019 in Current Hematologic Malignancy Reports
Verified
Journal Article
Closed access
PDF file
MYMarjan Yaghmaie
Marjan Yaghmaie
CYCecilia Cs Yeung
Cecilia Cs Yeung

1 January 2018 in Blood Research
Verified
Journal Article
Open access
PDF file
AAAbdolrahim Ahmadi
Abdolrahim Ahmadi
SKSaeid Kaviani
Saeid Kaviani
MYMarjan Yaghmaie
Marjan Yaghmaie
HPHossein Pashaiefar
Hossein Pashaiefar
MAMohammad Ahmadvand
Mohammad Ahmadvand
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
Ahmadi A, et al. Blood Res. 2018 Dec;53(4):320-324. https://doi.org/10.5045/br.2018.53.4.320

1 May 2008
Verified
Journal Article
Closed access
MYMarjan Yaghmaie
Marjan Yaghmaie
SGSeyed H. Ghaffari
Seyed H. Ghaffari
AGArdashir Ghavamzadeh
Ardashir Ghavamzadeh
KAKamran Alimoghaddam
Kamran Alimoghaddam
MJMohammad Jahani
Mohammad Jahani
IBIsa Bibordi
Isa Bibordi

20 January 2022 in Case Reports in Hematology
Verified
Journal Article
Open access
PDF file
MBMaryam Barkhordar
Maryam Barkhordar
FRFatemeh Tajic Rostami
Fatemeh Tajic Rostami
MYMarjan Yaghmaie
Marjan Yaghmaie
MAMehrdad Abbaszadeh
Mehrdad Abbaszadeh
BCBahram Chahardouli
Bahram Chahardouli
SMSeied Asadollah Mousavi
Seied Asadollah Mousavi
Coronavirus infectious disease-19 (COVID-19) usually alters the innate and adaptive immune setting by excessive production of proinflammatory cytokines, leading to a deviation in the natural course of simultaneous malignant disease. In the absence of disease-modifying therapy, complete remission of acute myeloid leukemia (AML) is an extraordinary event caused mainly by an immune-related mechanism secondary to a severe infectious process. We present a 57-year-old woman with a new diagnosis of AML associated with a 11q23/KMT2A abnormality who had achieved temporary spontaneous remission in the absence of disease-modifying therapy following the severe pulmonary infection with coronavirus lasting for six months. We review the literature and explain the potential impact of stimulated immune responses by COVID-19 on induction of remission in a patient with AML that could provide an excellent opportunity for new immune-based therapies to evolve for the hematologic malignancies. Despite the high ability of the immune process to destroy the malignant cells, the remission of duration is usually short. Therefore, it seems that continuing treatment after SR of AML by a consolidation regimen or bone marrow transplantation, based on a risk-adapted treatment approach, may reduce the recurrence risk.

1 March 2018
Verified
Journal Article
Closed access
PDF file
AMAkram Mirzaei
Akram Mirzaei
SMSaeed Mohammadi
Saeed Mohammadi
SGSeyed H. Ghaffari
Seyed H. Ghaffari
MYMarjan Yaghmaie
Marjan Yaghmaie
MVMohammad Vaezi
Mohammad Vaezi
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh

28 August 2019 in Iranian Biomedical Journal
Verified
Journal Article
Open access
PDF file
FNFatemeh Nevisi
Fatemeh Nevisi
MYMarjan Yaghmaie
Marjan Yaghmaie
HPHossein Pashaiefar
Hossein Pashaiefar
KAKamran Alimoghaddam
Kamran Alimoghaddam
MIMasoud Iravani
Masoud Iravani
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
Background: The analysis of the gene copy number alterations in tumor samples are increasingly used for diagnostic and prognostic purposes in patients with gastric cancer (GC). However, these procedures are not always applicable due to their invasive nature. In this study, we have analyzed the copy number alterations of five ...